Galera Therapeutics, Inc. (GRTX)
USD 0.02
(8.11%)
USD 0.02
(8.11%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 157.32 Million USD | 2.68% |
| 2022 | 153.21 Million USD | 8.42% |
| 2021 | 141.31 Million USD | 81.22% |
| 2020 | 77.98 Million USD | 45.03% |
| 2019 | 53.76 Million USD | -72.12% |
| 2018 | 192.87 Million USD | 103.08% |
| 2017 | 94.97 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 154.41 Million USD | 0.05% |
| 2024 Q1 | 154.34 Million USD | -1.9% |
| 2023 Q4 | 157.32 Million USD | -4.26% |
| 2023 Q2 | 163.27 Million USD | 3.78% |
| 2023 Q1 | 157.32 Million USD | 2.68% |
| 2023 FY | 157.32 Million USD | 2.68% |
| 2023 Q3 | 164.33 Million USD | 0.65% |
| 2022 Q3 | 148.21 Million USD | 2.7% |
| 2022 Q1 | 141.57 Million USD | 0.18% |
| 2022 FY | 153.21 Million USD | 8.42% |
| 2022 Q4 | 153.21 Million USD | 3.37% |
| 2022 Q2 | 144.32 Million USD | 1.95% |
| 2021 Q1 | 81.05 Million USD | 3.95% |
| 2021 FY | 141.31 Million USD | 81.22% |
| 2021 Q4 | 141.31 Million USD | -0.43% |
| 2021 Q3 | 141.93 Million USD | 0.81% |
| 2021 Q2 | 140.78 Million USD | 73.68% |
| 2020 Q3 | 73.38 Million USD | -0.92% |
| 2020 Q2 | 74.05 Million USD | -4.75% |
| 2020 Q1 | 77.75 Million USD | 44.61% |
| 2020 FY | 77.98 Million USD | 45.03% |
| 2020 Q4 | 77.98 Million USD | 6.27% |
| 2019 FY | 53.76 Million USD | -72.12% |
| 2019 Q3 | 224.37 Million USD | 342.33% |
| 2019 Q2 | 50.72 Million USD | 0.0% |
| 2019 Q1 | - USD | -100.0% |
| 2019 Q4 | 53.76 Million USD | -76.04% |
| 2018 Q4 | 192.87 Million USD | 0.0% |
| 2018 FY | 192.87 Million USD | 103.08% |
| 2017 FY | 94.97 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| America Great Health | 4.82 Million USD | -3160.666% |
| Ampio Pharmaceuticals, Inc. | 2.37 Million USD | -6521.465% |
| Aridis Pharmaceuticals, Inc. | 38.92 Million USD | -304.156% |
| Biora Therapeutics, Inc. | 132.63 Million USD | -18.615% |
| Bio-Path Holdings, Inc. | 2.77 Million USD | -5561.245% |
| Better Therapeutics, Inc. | 23.84 Million USD | -559.869% |
| Calithera Biosciences, Inc. | 8.28 Million USD | -1799.155% |
| Comera Life Sciences Holdings, Inc. | 9.97 Million USD | -1477.329% |
| Gene Biotherapeutics, Inc. | - USD | -Infinity% |
| eFFECTOR Therapeutics, Inc. | 26.33 Million USD | -497.312% |
| Eloxx Pharmaceuticals, Inc. | 31.78 Million USD | -395.0% |
| Evelo Biosciences, Inc. | 69.43 Million USD | -126.587% |
| Evolutionary Genomics, Inc. | 7.94 Million USD | -1880.043% |
| Finch Therapeutics Group, Inc. | 48.11 Million USD | -227.006% |
| Innovation1 Biotech Inc. | 3.5 Million USD | -4387.392% |
| Kiromic BioPharma, Inc. | 21.28 Million USD | -638.974% |
| Molecular Templates, Inc. | 31.17 Million USD | -404.719% |
| Navidea Biopharmaceuticals, Inc. | 12.51 Million USD | -1157.108% |
| NexImmune, Inc. | 5.08 Million USD | -2994.391% |
| Orgenesis Inc. | 35.53 Million USD | -342.735% |
| Panbela Therapeutics, Inc. | 16.51 Million USD | -852.798% |
| Point of Care Nano-Technology, Inc. | 266.41 Thousand USD | -58953.203% |
| PaxMedica, Inc. Common Stock | 2.29 Million USD | -6754.172% |
| Scopus BioPharma Inc. | 7.45 Million USD | -2010.502% |
| Sorrento Therapeutics, Inc. | 494.5 Million USD | 68.185% |
| Statera Biopharma, Inc. | 22.67 Million USD | -593.786% |
| TRACON Pharmaceuticals, Inc. | 10.91 Million USD | -1341.506% |
| Trevena, Inc. | 48.26 Million USD | -225.983% |
| Vaxxinity, Inc. | 30.94 Million USD | -408.422% |
| Vaccinex, Inc. | 5.94 Million USD | -2547.694% |
| Vicapsys Life Sciences, Inc. | 1.96 Million USD | -7892.839% |
| Viracta Therapeutics, Inc. | 38.37 Million USD | -309.991% |
| ZIVO Bioscience, Inc. | 2.76 Million USD | -5597.001% |